---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-033460"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2023-07-19T23:59:59+00:00"
generated_at: "2026-06-13T06:21:18.786909+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# HeartSciences reports FY2023 progress; MyoVista pivotal study enrollment complete

## Summary
- Completed patient enrollment for MyoVista wavECG pivotal study; FDA submission on track for later 2023.
- Expanded IP portfolio to 40 granted patents, including US, Korean, and Israeli patents for AI ECG.
- Entered multi-year AI ECG algorithm development collaboration with Rutgers University health system.
- Cash and cash equivalents $1.7M as of April 30, 2023; no revenue (development-stage company).
- AMA issued new Category III reimbursement codes for AI ECG risk assessment, validating market.

## SEC filing metadata
- accession: 0000950170-23-033460
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2023-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000095017023033460/0000950170-23-033460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000095017023033460/hscs-20230719.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-033460
- JSON: https://secwatch.observer/filing/0000950170-23-033460.json
- Plain text: https://secwatch.observer/filing/0000950170-23-033460.txt

## Key facts
- Earnings Releases
  HeartSciences Inc. reported financial results for fiscal year ended April 30, 2023.
  - Period: fiscal year ended April 30, 2023
  - Result: reported results
  source text: Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today provided a business update and reported financial results for the fiscal year ended April 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468492/000095017023033460/0000950170-23-033460-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.